Clinical Trial Update: A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers) [Phase 1]

View source ↗

Summary

This clinical trial update describes a Phase 1 study of AZD2962, an IRAK4 inhibitor, in participants with hematologic neoplasms, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Neoplasms

Drugs mentioned

• AZD2962 (AZD2962)

Snippet

Sponsor: AstraZeneca | Conditions: Haematologic Neoplasms | Phase 1 | Status: RECRUITING